Dr Arpan M Bhakta, MD - Medicare Anesthesiology in Everett, WA

Dr Arpan M Bhakta, MD is a medicare enrolled "Anesthesiology" physician in Everett, Washington. He went to University Of Texas Medical Branch At Galveston and graduated in 2004 and has 20 years of diverse experience with area of expertise as Anesthesiology. He is a member of the group practice Sutter Bay Medical Foundation and his current practice location is 1321 Colby Ave, Everett, Washington. You can reach out to his office (for appointments etc.) via phone at (425) 261-2000.

Dr Arpan M Bhakta is licensed to practice in Washington (license number MD60099225) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1417160250.

Contact Information

Dr Arpan M Bhakta, MD
1321 Colby Ave,
Everett, WA 98201-1665
(425) 261-2000
(425) 261-4462



Physician's Profile

Full NameDr Arpan M Bhakta
GenderMale
SpecialityAnesthesiology
Experience20 Years
Location1321 Colby Ave, Everett, Washington
Accepts Medicare AssignmentsYes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Dr Arpan M Bhakta attended and graduated from University Of Texas Medical Branch At Galveston in 2004
  NPI Data:
  • NPI Number: 1417160250
  • Provider Enumeration Date: 05/08/2007
  • Last Update Date: 10/15/2009
  Medicare PECOS Information:
  • PECOS PAC ID: 7012081607
  • Enrollment ID: I20190606002008

Medical Identifiers

Medical identifiers for Dr Arpan M Bhakta such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1417160250NPI-NPPES
8545261MedicaidWA

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207L00000XAnesthesiology MD60099225 (Washington)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
Sutter Delta Medical CenterAntioch, CAHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
Sutter Bay Medical Foundation42845387782941

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Arpan M Bhakta allows following entities to bill medicare on his behalf.
Entity NameSutter Bay Medical Foundation
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1013950807
PECOS PAC ID: 4284538778
Enrollment ID: O20031125000909

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Entity NameCounty Of San Mateo
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1679642326
PECOS PAC ID: 9032023171
Enrollment ID: O20031126000292

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Entity NameCounty Of San Mateo
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1831268580
PECOS PAC ID: 9032023171
Enrollment ID: O20040123000822

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Entity NameCounty Of San Joaquin
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1801830583
PECOS PAC ID: 6002703436
Enrollment ID: O20040301001287

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Entity NameFirst Choice Physician Partners
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1104183052
PECOS PAC ID: 0941465322
Enrollment ID: O20120710000480

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Entity NameCep America - Anesthesia Pc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1790401438
PECOS PAC ID: 3678897915
Enrollment ID: O20150115001110

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Entity NameG2 Anesthesia Pc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1487214698
PECOS PAC ID: 3375873599
Enrollment ID: O20191001001034

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Entity NameHenry Hu Md A Professional Corporation
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1659906337
PECOS PAC ID: 3274964580
Enrollment ID: O20200520000918

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more Medical News

› Verified 6 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Arpan M Bhakta is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Dr Arpan M Bhakta, MD
10 Commerce Dr,
New Rochelle, NY 10801-5214

Ph: (914) 637-3510
Dr Arpan M Bhakta, MD
1321 Colby Ave,
Everett, WA 98201-1665

Ph: (425) 261-2000

News Archive

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

New, shorter tuberculosis treatments could advance control

The introduction of new, shorter treatments for tuberculosis could have a dramatic effect on global efforts to reduce the number of cases and deaths from tuberculosis, according to a new study published in PLoS Medicine.

Cell signaling in cervical cancer; gene variant impairs glycogen synthesis

The March of Dimes and seven former directors of the U.S. Centers for Disease Control and Prevention (CDC) today urged parents not to be frightened of childhood vaccines by the suggestion in an upcoming episode of the ABC-TV drama, "Eli Stone" that the mercury-based preservative thimerosal - which is no longer used in vaccines may lead to autism.

Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.

Read more News

› Verified 6 days ago


Anesthesiology Doctors in Everett, WA

James Raymond Larson,
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 1321 Colby Ave, Everett, WA 98201
Phone: 425-258-3678    Fax: 425-258-3048
Robert E Vanvalkenburgh,
Anesthesiology
Medicare: Not Enrolled in Medicare
Practice Location: 1321 Colby Ave, Everett, WA 98201
Phone: 425-258-3678    Fax: 425-258-3048
Robert Kurt Bechtel,
Anesthesiology
Medicare: Medicare Enrolled
Practice Location: 1321 Colby Ave, Everett, WA 98201
Phone: 425-258-3678    Fax: 425-258-3048
Dr. Daniel N. Schneeweiss, M.D.
Anesthesiology
Medicare: Not Enrolled in Medicare
Practice Location: 1321 Colby Ave, Everett, WA 98201
Phone: 425-261-2000    Fax: 425-261-4462
Dr. Roxanne E Hertzog, M.D.
Anesthesiology
Medicare: Medicare Enrolled
Practice Location: 1100 Pacific Ave, Suite 100, Everett, WA 98201
Phone: 206-244-1212    Fax: 206-244-1223
Dr. Eric Breeden, M.D.
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 1321 Colby Ave, Providence Washington Anesthesia Services, Everett, WA 98201
Phone: 425-404-5352    Fax: 425-404-5357
Dr. Colin Seale Smith, D.O.
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 1700 13th Street Everett, Wa 98201, Everett, WA 98201
Phone: 425-621-2000    

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.